Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Verzenios Summary of Product Characteristics (SmPC)

Is Verzenios® ▼ (abemaciclib) dose adjustment required for patients with hepatic impairment?

Abemaciclib dose adjustments are only required for patients with with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients.

UK_cFAQ_ABE013_Z2_HEPATIC_IMPAIRMENT
UK_cFAQ_ABE013_Z2_HEPATIC_IMPAIRMENT
en-GB

Relative Potency and Half-Life of Abemaciclib increases in Patients with Severe Hepatic Impairment

No dose adjustments are necessary in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1 

Abemaciclib is metabolised in the liver.

Mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had no effect on the exposure of abemaciclib. In severe hepatic impairment (Child Pugh C), the potency adjusted unbound abemaciclib plus its active metabolites increased 2.4-fold. The half‑life of abemaciclib increased from 24 to 55 hours.1

References

1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: October 23, 2019


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request